STORM’s METTL3 Inhibitor Effective Against AML

Plans Global Clinical RNA Epigenetic Drug Program in early 2022

 
• By Sten Stovall

Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.

Emerging Company Profile Regular column feature image Version 2
STORM is targeting RNA modifying enzymes for development of new anti-cancer drugs • Source: Informa

More from Emerging Company Profiles

More from Start-Ups & SMEs